Division of Nephrology, San Francisco VA Medical Center/University of California, San Francisco, California, United States of America.
Department of Medicine, University of California San Francisco/ San Francisco VA Medical Center, San Francisco, California, United States of America.
PLoS One. 2018 Dec 17;13(12):e0208042. doi: 10.1371/journal.pone.0208042. eCollection 2018.
Patients with chronic kidney disease (CKD) are at increased risk for heart failure (HF). We aimed to investigate differences in proteins associated with HF hospitalizations among patients with and without CKD in the Heart and Soul Study.
We measured 1068 unique plasma proteins from baseline samples of 974 participants in The Heart and Soul Study who were followed for HF hospitalization over a median of 7 years. We sequentially applied forest regression and Cox survival analyses to select prognostic proteins. Among participants with CKD, four proteins were associated with HF at Bonferroni-level significance (p<2.5x10(-4)): Angiopoietin-2 (HR[95%CI] 1.45[1.33, 1.59]), Spondin-1 (HR[95%CI] 1.13 [1.06, 1.20]), tartrate-resistant acid phosphatase type 5 (HR[95%CI] 0.65[0.53, 0.78]) and neurogenis locus notch homolog protein 1 (NOTCH1) (HR[95%CI] 0.67[0.55, 0.80]). These associations persisted at p<0.01 after adjustment for age, estimated glomerular filtration and history of HF. CKD was a significant interaction term in the associations of NOTCH1 and Spondin-1 with HF. Pathway analysis showed a trend for higher representation of the Cardiac Hypertrophy and Complement/Coagulation pathways among proteins prognostic of HF in the CKD sub-group.
These results suggest that markers of heart failure differ between patients with and without CKD. Further research is needed to validate novel markers in cohorts of patients with CKD and adjudicated HF events.
患有慢性肾病(CKD)的患者心力衰竭(HF)的风险增加。我们旨在研究 Heart and Soul 研究中患有和不患有 CKD 的患者中与 HF 住院相关的蛋白质的差异。
我们从 Heart and Soul 研究的 974 名参与者的基线样本中测量了 1068 种独特的血浆蛋白,这些参与者在中位 7 年的时间内接受了 HF 住院治疗。我们依次应用森林回归和 Cox 生存分析来选择预后蛋白。在患有 CKD 的参与者中,有四种蛋白质与 HF 相关,达到 Bonferroni 水平的显著性(p<2.5x10(-4)):血管生成素-2(HR[95%CI] 1.45[1.33, 1.59])、Spondin-1(HR[95%CI] 1.13 [1.06, 1.20])、抗酒石酸酸性磷酸酶 5 型(HR[95%CI] 0.65[0.53, 0.78])和神经生成基因座 Notch 同源蛋白 1(NOTCH1)(HR[95%CI] 0.67[0.55, 0.80])。在调整年龄、估计肾小球滤过率和 HF 病史后,这些关联仍保持 p<0.01。NOTCH1 和 Spondin-1 与 HF 的关联中,CKD 是一个显著的交互项。途径分析显示,在 CKD 亚组中,与 HF 预后相关的蛋白质中,心脏肥大和补体/凝血途径的代表性更高。
这些结果表明,心力衰竭的标志物在患有和不患有 CKD 的患者之间存在差异。需要进一步的研究来验证在患有 CKD 和经裁决的 HF 事件的患者队列中新型标志物的有效性。